Enhance your practice with CME and tools that focus on the management of neurological conditions.
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
11:45 AM - 12:45 PM ET
Orlando, Florida
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
Aaron Miller, MD
Nutrition and the Gut-Brain Connection in Schizophrenia
Shelina Ramnarine, PhD
Deanna L. Kelly, PharmD, BCPP
Challenging the Status Quo in Schizophrenia Treatment
Stephen Marder, MD
The Social Brain in Schizophrenia
Michael Green, PhD
Target Locked in gMG: Why T2T Matters
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Minimal By Design: Define MSE Endpoints
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
The 2-Point Signal: Apply ≥2-Point Rule
When to Begin FcRn: Initiation Criteria, Key Evidence
Proactive Pregnancy Planning and Reproductive Care in MS
Riley Bove, MD, MMSc
Advancing Pediatric MS Care: Insights from AAN 2026
Elizabeth Wilson, MD
Emerging Serum microRNAs as Early Signals in MS
Depression as a Signal of MS Progression
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Escalate With Intention: Stepwise, Target-Anchored Moves
The IgG Clock: Redose Using IgG Kinetics
Shared Goals, Shared Gains: Align With Patient Preferences
Loading...
We're glad to see you're enjoying Global Neurology Academy… but how about a more personalized experience?
Press cancel to remain on Global Neurology Academy. Press the link below or the continue button to keep going.